Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.

King JR, Acosta EP, Yogev R, Wiznia A, Kraimer J, Graham B, Carey V, Britto P, Jean-Philippe P, Moye J, Watson D.

Pediatr Infect Dis J. 2009 Feb;28(2):159-61. doi: 10.1097/INF.0b013e3181861d8b.

2.

Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.

Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.

Antivir Ther. 2007;12(6):963-9.

PMID:
17926651
3.

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

Bergshoeff AS, Fraaij PL, Ndagijimana J, Verweel G, Hartwig NG, Niehues T, De Groot R, Burger DM.

J Acquir Immune Defic Syndr. 2005 May 1;39(1):63-8.

PMID:
15851915
4.

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, Havens PL; PACTG 1038 Team..

Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08.

5.

Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.

Rosso R, Di Biagio A, Dentone C, Gattinara GC, Martino AM, Viganò A, Merlo M, Giaquinto C, Rampon O, Bassetti M, Gatti G, Viscoli C.

J Antimicrob Chemother. 2006 Jun;57(6):1168-71.

PMID:
16606636
6.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
7.

Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

Neely MN, Rakhmanina NY.

J Antimicrob Chemother. 2010 Apr;65(4):808-9; author reply 809-10. doi: 10.1093/jac/dkp489. No abstract available.

PMID:
20086000
8.

The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.

Josephson F, Andersson MC, Flamholc L, Gisslén M, Hagberg L, Ormaasen V, Sönnerborg A, Vesterbacka J, Böttiger Y.

Eur J Clin Pharmacol. 2010 Apr;66(4):349-57. doi: 10.1007/s00228-009-0763-z.

PMID:
19967342
9.

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

van der Lee M, Verweel G, de Groot R, Burger D.

Antivir Ther. 2006;11(4):439-45.

PMID:
16856617
10.

Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K.

J Antimicrob Chemother. 2009 Nov;64(5):1080-6. doi: 10.1093/jac/dkp322.

PMID:
19729375
11.

Lopinavir exposure with an increased dose during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS; PACTG 1026s Study Team..

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):485-91. doi: 10.1097/QAI.0b013e318186edd0.

12.

Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.

la Porte C, van Heeswijk R, Mitchell CD, Zhang G, Parker J, Rongkavilit C.

Antivir Ther. 2009;14(4):603-6.

PMID:
19578247
13.

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, Foit C, Rynkiewicz K, Richards B, King M, Rode R, Kempf DJ, Granneman GR, Sun E.

Antimicrob Agents Chemother. 2003 Jan;47(1):350-9.

14.

Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.

Sierra-Madero J, Villasis-Keever A, Méndez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F, Juárez-Kasusky I, Magana-Aquino M, Ramos-Santos C, Pérez-Saleme L, Rangel-Frausto S, Antuna-Puente B, Soto-Ramírez LE, Lima V, Belaunzarán-Zamudio F, Crabtree-Ramírez B, Montaner J.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):582-8. doi: 10.1097/QAI.0b013e3181cae4a1.

PMID:
20090545
15.

Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.

Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR.

J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):561-6. doi: 10.1097/QAI.0b013e31817bebeb.

16.

Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.

McIlleron H, Ren Y, Nuttall J, Fairlie L, Rabie H, Cotton M, Eley B, Meyers T, Smith PJ, Merry C, Maartens G.

Antivir Ther. 2011;16(3):417-21. doi: 10.3851/IMP1757.

PMID:
21555825
17.

Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.

López Aspiroz E, Santos Buelga D, Cabrera Figueroa S, López Galera RM, Ribera Pascuet E, Domínguez-Gil Hurlé A, García Sánchez MJ.

Ther Drug Monit. 2011 Oct;33(5):573-82. doi: 10.1097/FTD.0b013e31822d578b.

PMID:
21912331
18.

Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

Dlamini JN, Hu Z, Somaroo H, Highbarger HC, Follmann DA, Dewar RL, Pau AK.

Pharmacotherapy. 2011 Feb;31(2):158-63. doi: 10.1592/phco.31.2.158.

19.

Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.

van der Lee M, Sankatsing R, Schippers E, Vogel M, Fätkenheuer G, van der Ven A, Kroon F, Rockstroh J, Wyen C, Bäumer A, de Groot E, Koopmans P, Stroes E, Reiss P, Burger D.

Antivir Ther. 2007;12(7):1127-32.

PMID:
18018771
20.

The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.

Crommentuyn KM, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL, Huitema AD, Beijnen JH.

Antivir Ther. 2004 Oct;9(5):779-85.

PMID:
15535416

Supplemental Content

Support Center